Clinical Trial Search

Primary: Changes in Blood Flow Through the Vertebral Artery and Posterior Cerebral and Cerebellar Circulation — 15.5; 15.1; 14.7 cm/s

Primary: Fatal and Nonfatal Ischemic Stroke in the Vertebrobasilar Territory — 72 Participants

Primary: All Cause Mortality at 30 Days Post-procedure — 3 Participants

Primary: All Cause Mortality. — 4 participants

Primary: Change of Subclavian Flow to Normal Flow Pattern During Cuff Test — 0; 2 participants

Primary: Number of Participants With Neurologic Death or Major Ipsilateral Stroke Within 12 Month Follow-up Period. — 5 Participants

Primary: Measurement Bias of Calcification Analyzed by vascuCAP™ Non-invasively Relative to Histopathology as Ground Truth. — -0.47; .07 mm2

Primary: Technical Failure Rate — 3.55; 29.22; 1.57; 17.65 percentage of arterial segments

Primary: Technical Failure Rate — 4.65; 29.44; 1.77; 16.70 percentage of arterial segments

Primary: Death or Neurologic Disability, Defined as an National Institutes of Health Stroke Scale (NIHSS)>4 or American Spinal Injury Association (ASIA) Lower Extermity Motor…

Primary: Evidence of Carotid Artery or Intracranial Artery Atherosclerosis Confirmed by Vascular Ultrasonography — 96; 1063; 826; 241 artery numbers

Primary: Number of Participants With Progression of Symptomatic Intracranial Stenosis — 20; 32 participants

Primary: Number of Participants With Major Adverse Events — 0 number of serious adverse events

Primary: Stroke or Death in the Territory of Qualifying Artery — 5 Participants — p=0.08

Primary: Incidence of Ipsilateral New White Lesions, by Patient — 12 Participants

Primary: Procedural Success — 64 Vessels Treated

Primary: Composite of Partial or No False Lumen Thrombosis, Aortic Rupture, and Aortic Dilatation — 15; 31 participants — p=<0.001

Primary: Number of Participants With Freedom From Major Adverse Events — 48 participants

Primary: Number of Patients With Major Complications — 2; 4; 2; 3 participants

Primary: Change in Montreal Cognitive Assessment (MoCA) Score — 0.56; 1.38; -0.75; 0.50 score on a scale

Primary: Disease-, Procedure- or Device-related Mortality at 12 Months Post-procedure — 9; 1; 1 participants

Primary: Time From Emergency Room Arrival to Initiation of Endovascular Stroke Therapy ("Door-to-groin" Time) — 100; 88 minutes

Primary: Number of Participants With Poor Stroke Outcome at Hospital Discharge as Measured by the Modified Rankin Scale (mR 3-6) — 84; 99; 96; 87 Participants

Primary: Number of CDU False-positive Patients — 73; 63; 0; 29 Participants

Primary: Percentage of Patients Experiencing Major Adverse Events (MAE) — 6.9 percentage of participants

Primary: All-cause Mortality Incidence Through 30 Days Post-treatment — 5 participants — p=.006

Primary: Target Volume Difference Between Standard of Care vs. CT Angiogram and MRI Alone — 1.1; 1.3 mL

Primary: Radical Peripapillary Capillaries Vessel Density — 55.95; 57.24 percentage of vessel

Primary: Primary Outcome — 27; 21 Participants

Primary: Hemodynamic Parameters (Change From Baseline Systolic Blood Pressure (Pre-infusion) Over Time Until 135 Minutes Post-infusion) — -8; -3.4 mmHg